Search Results - "Malpica‐Castillo, Luis E."
-
1
-
2
Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder
Published in International journal of dermatology (02-07-2024)“…Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (PCSM-LPD) is an increasingly recognized entity with heterogeneous management…”
Get full text
Journal Article -
3
Ultra–Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung
Published in Advances in radiation oncology (01-12-2024)“…Definitive intent radiation therapy (RT) for early-stage mucosa-associated lymphoid tissue (MALT) lymphoma typically includes a dose of 24 to 30 Gy. While…”
Get full text
Journal Article -
4
Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
Published in Advances in radiation oncology (01-11-2023)“…Purpose: Radiation therapy (RT) and the antibody-drug conjugate brentuximab vedotin (BV) are standard-of-care treatment options for patients with certain B and…”
Get full text
Journal Article -
5
-
6
Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study
Published in JCO global oncology (01-08-2022)“…PURPOSEWaldenstrom Macroglobulinemia (WM) is a rare lymphoma with distinct clinical features, and data from Latin American patients are lacking. Therefore, we…”
Get full text
Journal Article -
7
Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders
Published in Blood (13-11-2019)“…▪ Background: The use of immunosuppressive therapies in the management of non-malignant immune-mediated hematologic disorders (NMIHD) leads to an increased…”
Get full text
Journal Article -
8
Incidence and Time Course of Neutropenia in Patients Treated with Rituximab-Based Therapy for Non-Malignant Immune-Mediated Hematologic Diseases
Published in Blood (13-11-2019)“…Background: Rituximab (RTX) is approved for various malignant hematologic and rheumatologic disorders. A noteworthy side effect, late-onset neutropenia, has…”
Get full text
Journal Article -
9
Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)
Published in Blood (15-11-2022)Get full text
Journal Article -
10
A Retrospective Study on Prephase Therapy Prior to Definitive Multiagent Chemotherapy in Aggressive Lymphomas
Published in Blood (29-11-2018)“…Background: Diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) are aggressive lymphomas that evolve rapidly and are fatal if untreated. Most…”
Get full text
Journal Article -
11
Clinical Characteristics and Outcome of Diffuse Large B Cell Lymphoma Among HTLV-1 Carriers in Peru: A Matched Cohort Study
Published in Blood (05-11-2020)“…Background: Diffuse large B-cell lymphoma (DLBCL) is the most common variant of non-Hodgkin lymphoma (NHL) accounting for approximately 30% of the NHL cases…”
Get full text
Journal Article -
12
Clinical Features and Outcome of HTLV-1 Carriers Diagnosed with Hodgkin Lymphoma in Peru: A Matched Cohort Study
Published in Blood (05-11-2020)“…Background: The human T-cell lymphotropic virus type 1 (HTLV-1) is an oncogenic retrovirus that affects CD4+ T-cell lymphocytes and is the cause for adult…”
Get full text
Journal Article -
13
Impact of IRF4/MUM1 Expression on Adult T-Cell Leukemia/Lymphoma and Treatment Outcome
Published in Blood (08-12-2017)“…Introduction: HTLV-1 related adult T-cell leukemia-lymphoma (ATLL) remains fatal, thus urging development of new therapies. Interferon regulatory factor 4…”
Get full text
Journal Article -
14
CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
Published in Blood (15-11-2022)Get full text
Journal Article -
15
Targeting CD30 Expression in Adult T-Cell Leukemia-Lymphoma (ATLL)
Published in Blood (08-12-2017)“…▪ Introduction: Adult T-cell leukemia-lymphoma (ATLL) is caused by HTLV-1, and carries a dismal prognosis urging the development of new therapies. CD30…”
Get full text
Journal Article -
16
Epidemiology, Clinical Features, and Outcome of HTLV-1 Related Adult T-Cell Leukemia-Lymphoma in a Prevalent Area in the United States
Published in Blood (08-12-2017)“…▪ Introduction: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive, peripheral T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1)…”
Get full text
Journal Article -
17
Identifying a Simple Clinical Prognostic Model for Aggressive Adult T-Cell Leukemia/Lymphoma in Latin American Population and Its Validation: A Large International Study of the Latin America Working Group for Lymphomas (GELL)
Published in Blood (13-11-2019)“…Background: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive, peripheral T-cell neoplasm associated with the human T-cell leukemia virus type 1 (HTLV-1)…”
Get full text
Journal Article -
18
Serum Albumin Is an Independent Factor Predicting Survival in Patients with Peripheral T Cell Lymphoma: A Multi-Institutional Study from the Latin American Working Group for Lymphomas (GELL)
Published in Blood (13-11-2019)“…Introduction: Peripheral T cell lymphoma (PTCL) is a very heterogenous disease and corresponds to approximately 15% of all non-Hodgkin lymphoma cases. PTCL is…”
Get full text
Journal Article -
19
Impact of Cutaneous Involvement on the Clinical Outcome of Adult T-Cell Leukemia/Lymphoma: A Study from the Latin American Group of Lymphoproliferative Disorders (GELL)
Published in Blood (05-11-2020)“…INTRODUCTION: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive peripheral T-cell neoplasm caused by the Human T-cell Leukemia Virus Type 1 (HTLV-1)…”
Get full text
Journal Article -
20
Follicular Lymphoma in Latin America: Real-World Experience from 763 Patients
Published in Blood (05-11-2020)“…Introduction: Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma subtype seen in Western countries. However, data on FL from Latin…”
Get full text
Journal Article